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Introduction {#sec2}
============

It is widely acknowledged that there is a significant and unmet need for new antibacterial compounds because of the growing and global problem of antibiotic resistance. At present, significant discovery efforts in this area are focused on the chemical evolution of existing antibiotic classes to circumvent resistance ([@bib21]). Alternatively, searches for new compounds are routinely initiated with high-throughput screens of vast compound libraries to identify chemical matter that specifically inhibits the growth of target pathogens ([@bib47]) or directly inhibits a particular resistance mechanism ([@bib45]). Screens against specific molecular targets, reconstituted *in vitro*, have also served to provide lead compounds for antibiotic development ([@bib20]). All these approaches have merits; however, given the lack of new antibacterial scaffolds in clinical trials, it is clear that new thinking is also needed. For example, compounds that interfere with specific metabolic states ([@bib24]), previously untargeted molecular processes ([@bib27]), or bacterial morphology ([@bib5]) also have significant potential for antibiotic discovery. We have taken a unique approach by screening against the sporulation pathway in the bacterial genus *Streptomyces.*

The streptomycetes are filamentous bacteria that exhibit a complex multicellular life cycle. This life cycle starts with spore germination, continues with the growth of vegetative "substrate hyphae," followed by the erection of a fuzzy layer of "aerial hyphae" on the colony surface. The aerial hyphae then undergo a concerted round of cell division that divides each filament into a chain of unigenomic compartments that then mature into spores ([@bib38]). In contrast, the substrate hyphae are sites of "secondary metabolism" that generate antibacterial compounds, which, in nature, are believed to protect the developing colony from competing microorganisms ([@bib7]). Each stage of this process is accompanied by a visual phenotype: defects in spore maturation manifest as "white" mutants because the colonies are unable to synthesize the WhiE spore pigment that is believed to be the final step in this life cycle ([@bib19]).

In previous research, we have screened compound libraries for molecules that upregulate secondary metabolism in *Streptomyces coelicolor* ([@bib16], [@bib41]). We noted in this and subsequent work that some of the compounds we discovered appeared to have effects on other aspects of the streptomycetes life cycle, including sporulation ([@bib1]). Intriguingly, some of the compounds that target sporulation turned out to have antibacterial effects against rod-shaped and coccoid bacteria, such as *Bacillus subtilis* and *Staphylococcus aureus.* These molecules targeted cells in unusual ways that are clearly outside the most common suite of antibiotic targets: one compound blocked septation ([@bib29]) and another interfered with the relationship between cell growth and cell division ([@bib37]).

Having discovered that some inhibitors of the *Streptomyces* sporulation pathway have antibiotic activity against rod-shaped and coccoid bacteria, we decided to determine whether the opposite was also true. By screening antibiotics having known targets we report that compounds targeting the integrity of DNA confers a sporulation defect at sub-inhibitory concentrations, whereas compounds that target the ribosome, RNA polymerase, the cell wall, and the cell\'s electrochemical gradient have only a simple antibacterial effect. We leveraged this discovery by screening a small library of 3,705 synthetic compounds, previously demonstrated to have biological activity against Gram-positive bacteria ([@bib17], [@bib36]), for compounds having the capacity to inhibit sporulation in *Streptomyces venezuelae.* Here we report that the most potent of these is an inhibitor of DNA gyrase identified as EN-7.

Results {#sec3}
=======

The *Streptomyces venezuelae* Sporulation Program Is Sensitive to DNA Damage {#sec3.1}
----------------------------------------------------------------------------

To determine the effect of chemical inhibitors on morphogenesis in *S. venezuelae*, we applied antibiotics having diverse molecular targets at concentrations 5--10× their minimum inhibitory concentration (MIC) to filter disks on lawns of spores. We then observed how these molecules impacted growth and development ([Figure 1](#fig1){ref-type="fig"}A). Antibiotics such as rifampicin, triclosan, vancomycin, and kanamycin conferred a zone of inhibited growth as expected. Growth and sporulation were normal at concentrations below the MIC, as demonstrated by the green pigmentation of the lawn surface. This was also the effect of the ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP). In contrast, compounds that either directly target DNA or inhibit bacterial gyrase conferred a white phenotype at sub-inhibitory concentrations, consistent with a failure to produce the WhiE spore pigment associated with the completion of the *S. venezuelae* sporulation cycle ([@bib42], [@bib43]).Figure 1*S. venezuelae* Sporulation Is Sensitive to DNA Damage(A) *S. venezuelae* is treated with antibiotics of various targets to determine the impact on growth development. Following 48 h of incubation sporulation inhibition is visualized by the appearance of a white halo (*whi* phenotype) in the sub-MIC region surrounding the zone of inhibition. A white horizontal line has been added to the sporulation-deficient panes as a visual guide. Each disk is treated with 10 μL of the following antibiotics, 100 μg/mL rifampicin, 1 mg/mL triclosan, 100 μg/mL vancomycin, 250 μg/mL kanamycin, 3 mM CCCP, 100 μg/mL novobiocin, 250 μg/mL ciprofloxacin, 20 μg/mL mitomycin C, and 100 μg/mL bleomycin. The concentrations were selected in order to get a relatively consistent zone of inhibition between the various treatment molecules.(B) Scanning electron microscopy images near the zone of inhibition of *S. venezuelae* treated with kanamycin, rifampicin, mitomycin C, and ciprofloxacin.

To confirm that DNA damage blocked sporulation we carried out scanning electron microscopy (SEM) on a section of the *S. venezuelae* lawn immediately adjacent to the zone of inhibition formed by treatment with mitomycin C (DNA crosslinker), ciprofloxacin (gyrase inhibitor), kanamycin (translation inhibitor), and rifampicin (transcription inhibitor) ([Figure 1](#fig1){ref-type="fig"}B). We found that, while the kanamycin and rifampicin images show septated aerial hyphae, indicating sporulation, the samples treated with the DNA damage agents mitomycin C and ciprofloxacin do not show any aerial hyphae septation. This confirms that the white phenotype induced by these molecules is caused by an inhibition of *S. venezuelae* sporulation septation.

Screening for Novel Small-Molecule Sporulation Inhibitors {#sec3.2}
---------------------------------------------------------

To determine whether this phenomenon could be used to identify novel antimicrobial agents, we screened 3,705 synthetic bioactive small molecules ([@bib17]) via a disk diffusion assay for the capacity to block sporulation in *S. venezuelae* at sub-MIC concentrations. In this way, we identified ten compounds, all of which had antibacterial activity at higher concentrations but that conferred a reproducible white phenotype below the MIC ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Combining the effect on both growth and sporulation inhibition, the most potent of these molecules was EN-7 ([Figure 2](#fig2){ref-type="fig"}A). Treatment with a filter disk containing 10 μL of 2.5 mM EN-7 resulted in a significant zone of inhibition as well as a striking band of inhibited sporulation below the MIC for growth ([Figure 2](#fig2){ref-type="fig"}B). To confirm that the white phenotype in this zone was due to inhibited sporulation, green and white sections of the lawn were imaged by SEM. Consistent with our screening criteria, the green region showed a healthy lawn containing aerial hyphae septated into mature spores while the white region showed aerial hyphae without any septation. In spite of the exceptional EN-7 sensitivity of the *S. venezuelae* sporulation program, the compound conferred no other morphological defects.Figure 2EN-7 Inhibits *S. venezuelae* Growth and Sporulation(A) Chemical structure of EN-7.(B) Sporulation inhibition phenotype induced by EN-7. A section of the lawn was cut from the agar and both the treated (left) and untreated (right) sections imaged with scanning electron microscopy.

To determine the molecule\'s effect on non-streptomycetes we tested EN-7 against a series of three *S. aureus* and three *Escherichia coli* laboratory strains, as well as eight extensively resistant clinical *S. aureus* strains ([Table 1](#tbl1){ref-type="table"}). For the Gram-positive *S. aureus*, we found that the molecule had an MIC of 1 μM, or 0.4 μg/mL, against the three laboratory strains (ATCC 29213, TCH1516, and ATCC 33591) and four clinical strains (C0017, C0024, C0023, and C0019), an increased MIC of 4 μM against one of the clinical strains (C0112) and was inactive against the other three clinical strains (C0018, C0032, and C0117) at concentrations up to 128 μM. The antibiograms for these clinical strains indicated extensive antibiotic resistance to ciprofloxacin, clindamycin, erythromycin, levofloxacin, and oxacillin. In addition, the Comprehensive Antibiotic Resistance Database ([@bib30]) was used to identify many of the antibiotic resistance genes or modified targets within the genomes of these strains ([Table S1](#mmc1){ref-type="supplementary-material"}). While we could not find a definitive explanation for the difference in activity, it is clear that EN-7 is active against clinically relevant strains and can overcome a diverse range of resistance mechanisms. Against the Gram-negative *E. coli*, we observed no growth inhibition against the MC1061 ([@bib12]) or BW25113 ([@bib18]) strains at concentrations up to 64 μM but did observe an MIC of 1 μM against the outer-membrane and efflux-deficient *E. coli* BW25113 Δ*tolC* Δ*bamB* strain ([@bib33]). Thus, EN-7 is highly active against even extensively resistant *S. aureus*, and the resistance observed in Gram-negative *E. coli* is likely caused by an inability to enter the cell through the outer-membrane.Table 1MIC of EN-7 against Lab and Clinical Strains of *S. aureus* and *E. coli*SpeciesStrainMIC (μM)*S. aureus*ATCC 292131TCH 15161ATCC 335191C0117\>128C00231C01124C00171C0032\>128C0018\>128C00191C00241*E. coli*MC1061\>64BW25113\>64Δ*tolC* Δ*bamB*1

Since EN-7 is a hit from a synthetic small-molecule library, we wanted to confirm the molecule\'s structure to ensure the observed activity was not caused by a degradation product. The molecule was synthesized ([Figure S5](#mmc1){ref-type="supplementary-material"}) and confirmed that it has the same activity as the hit molecule from the library.

EN-7 Targets DNA Gyrase {#sec3.3}
-----------------------

To understand EN-7\'s mechanism of action, we raised nine EN-7^R^ mutants from *S. aureus* strain ATCC 29213. We isolated three such mutants using a serial passaging approach (mut-1, mut-2, and mut-3) and six more by direct plating on agar containing 10 μM, or 10× MIC, of EN-7 (mut-4 through mut-9).

We determined full-length chromosome sequences of the nine EN-7-resistant strains and found that each of them had acquired a point mutation in the *gyrAB* operon ([Table 2](#tbl2){ref-type="table"}). Three of the mutants had an altered GyrA sequence: A34T (mut-3 and mut-9) and P219Q (mut-6). The other six mutants had an altered GyrB sequence: K417E (mut-1, mut-2, mut-4, and mut-5) and D437N (mut-7 and mut-8). We confirmed the EN-7 resistance of these cultures using a broth dilution MIC assay, showing no activity up to 16 μM (16× MIC), the highest concentration tested ([Figure 5](#fig5){ref-type="fig"}).Table 2Summary of *S. aureus* EN-7-Resistant Mutant Strains and Corresponding AllelesMutant Allele*S. aureus* EN-7^R^ StrainsGyrA A34Tmut-3, mut-9GyrA P219Qmut-6GyrB K417Emut-1, mut-2, mut-4, mut-5GyrB D437Nmut-7, mut-8

To confirm that the mutations are the cause of the observed EN-7 resistance we selected the most common mutation, GyrB K417E, and reconstituted it in wild-type *S. aureus* ATCC 29213 through allelic exchange ([@bib39]). Because of the essential nature of gyrase, the allelic exchange was accomplished in a single step by spreading plasmid-containing cells as well as wild-type *S. aureus* ATCC 29213 cells to agar plates containing 10 μM EN-7 for final selection and 1 μg/mL anhydrotetracycline to activate the pIMAY anti-*secY* sequence and ensure the plasmid itself was not integrated into the chromosome. The plates were then incubated overnight at the plasmid non-replicating temperature of 37°C. Following overnight incubation, we observed approximately 50 colonies on each of the wild-type plates and over 2,000 on each of the plates containing the GyrB K417E allelic exchange strain ([Figure 3](#fig3){ref-type="fig"}A). We confirmed the loss of the plasmid by replicate plating with 10 μM EN-7 or 10 μM EN-7 with 25 μg/mL chloramphenicol, the antibiotic selection marker for the pIMAY plasmid, and observed no growth in the presence of chloramphenicol ([Figure 3](#fig3){ref-type="fig"}B). We tested three strains in a broth dilution assay and found that they were highly resistant to EN-7, up to 128 μM ([Figure 3](#fig3){ref-type="fig"}C). Finally, we confirmed the presence of the K417E mutation by amplifying and sequencing *gyrA* and *gyrB* from eight independent allelic exchange cultures ([Figure 3](#fig3){ref-type="fig"}D). Therefore, the gyrase mutations in the EN-7^R^ stains are sufficient to induce EN-7 resistance.Figure 3Allelic Exchange of EN-7 Resistance Mutations into *S. aureus*(A) Image of three replicate plates of the allelic exchange of the EN-7 resistance GyrB K417E mutation into *S. aureus* versus wild-type *S. aureus* following incubation in the presence of 1 μg/mL anhydrotetracycline and 10 μM EN-7 and incubated at the pIMAY non-replicating temperature of 37°C.(B) Replicate plating of 24 colonies from the allelic exchange plates in (A) to agar containing 10 μM EN-7 (left) and 10 μM EN-7 and 25 μg/mL chloramphenicol (right) demonstrating the loss of the pIMAY plasmid following allelic exchange.(C) Determining MIC of three of the replicate plated EN-7-resistant strains from (B) showing no EN-7 activity up to 128 μM relative to the MIC of 1 μM in the wild-type *S. aureus* ATCC 29213 strain.(D) Sequencing of the *gyrB* amplicon showing the point mutation in each of the tested allelic exchange strains (top) and the translation of the corresponding region showing the K417E amino acid substitution (bottom).

Gyrase and topoisomerase IV are both type IIA topoisomerases. DNA gyrase forms double-stranded breaks and reseals DNA to induce negative supercoiling, relieving torsional stress induced by transcription or replication, as well as relaxing positive supercoiling ([@bib46]). It is a tetramer composed of GyrA and GyrB (A~2~B~2~) that cleaves DNA through an active-site tyrosine located on each GyrA subunit, is highly conserved across bacteria, and its function can be inhibited through multiple mechanisms and by several different antibiotic classes. Topoisomerase IV, while also able to cleave and reseal double-stranded DNA and composed of a heterotetramer of ParC and ParE (C~2~E~2~), has a different function than gyrase. It is responsible for decatenating DNA following replication and relaxing positive DNA supercoils ([@bib9], [@bib28]).

To directly test EN-7 activity, we utilized a series of *in vitro* assays against purified *S. aureus* and *E. coli* gyrase and topoisomerase IV enzymes ([Figure 4](#fig4){ref-type="fig"}). First, we found that EN-7 inhibits *S. aureus* gyrase supercoiling activity with a half maximal inhibitory concentration (IC~50~) of 85 nM ([Figure 4](#fig4){ref-type="fig"}A) while inhibiting *E. coli* gyrase supercoiling at an IC~50~ of 1.75 μM ([Figure 4](#fig4){ref-type="fig"}B). The activity against topoisomerase IV-catalyzed decatenation was reversed, with inhibition of *E. coli t*opoisomerase IV at an IC~50~ of 0.89 μM ([Figure 4](#fig4){ref-type="fig"}C) with no activity against the *S. aureus* enzyme up to 100 μM ([Figure 4](#fig4){ref-type="fig"}D). To investigate possible mechanisms of gyrase inhibition, we found that EN-7 does not stabilize the gyrase-DNA double-stranded cleavage complex in a manner similar to fluoroquinolones but does increase the occurrence of DNA nicking ([Figure 4](#fig4){ref-type="fig"}E). Co-treatment with both ciprofloxacin and EN-7 does not prevent ciprofloxacin-induced formation of the double-stranded cleavage complex ([Figure 4](#fig4){ref-type="fig"}F), suggesting that EN-7 does not inhibit gyrase-DNA binding and acts in a manner that does not prevent the formation of the double-stranded break. In addition, EN-7 inhibits *S. aureus* gyrase-induced relaxation at an IC~50~ of 0.1--0.5 μM ([Figure 4](#fig4){ref-type="fig"}G). Since this process acts independently of ATPase activity, this inhibition confirms that the molecule does not act as an ATPase inhibitor. Finally, we found that *S. aureus* gyrase containing the fluoroquinolone resistance mutation GyrA S84L is inhibited by EN-7 at an IC~50~ of 9.96 μM, over a 100-fold increase relative to the wild-type enzyme ([Figure 4](#fig4){ref-type="fig"}H). This collection of *in vitro* assays demonstrates that EN-7 is a highly potent topoisomerase inhibitor that acts independently of conventional mechanisms while being less active, *in vitro*, against gyrase containing the GyrA S84L mutation.Figure 4*In Vitro* Inhibition of Topoisomerase Function by EN-7pBR322 DNA was incubated with gyrase or topoisomerase IV and different concentrations of compound and separated by agarose gel electrophoresis. (+) is a positive control with untreated enzyme, while (−) is a no-enzyme control. Labels indicate relaxed (R), supercoiled (SC), linear (L), catenated (C), and decatenated (D) DNA.(A) Inhibition of *S. aureus* gyrase supercoiling by EN-7.(B) Inhibition of *E. coli* gyrase supercoiling by EN-7.(C) Inhibition of *E. coli* topoisomerase IV decatenation by EN-7.(D) Inhibition of *S. aureus* topoisomerase IV decatenation by EN-7.(E) Unlike ciprofloxacin (CFX), EN-7 does not stabilize a double-stranded break DNA gyrase cleavage complex with *S. aureus* gyrase.(F) EN-7 does not inhibit the formation of ciprofloxacin (CFX) stabilized cleavage complex.(G) EN-7 and moxifloxacin (MOX) inhibit ATP-independent *S. aureus* gyrase-induced DNA relaxation.(H) The *S. aureus* gyrase mutant GyrA S84L is less susceptible to both MOX and EN-7.

We took two approaches to determine whether the EN-7^R^ mutations fall in previously identified functional regions of the DNA gyrase enzyme. First, we mapped them into an alignment of published GyrA and GyrB sequences from *S. aureus*, *E. faecalis*, *S. coelicolor*, *S. venezuelae*, *B. subtilis*, and *E. coli* ([Figure S4](#mmc1){ref-type="supplementary-material"}A). All four of the residues altered in EN-7^R^ strains are fully conserved across these six diverse bacteria. Second, we mapped our EN-7-resistant mutations to published gyrase structures in complex with ciprofloxacin (2XCT) and GSK299423 (2XCS), a novel bacterial topoisomerase inhibitor (NBTI) molecule and compared them to reported resistance mutations ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C) ([@bib4]). Although the mutations do not cluster around a specific binding site, all four of the mutations are distinct from common fluoroquinolone resistance mutations at GyrA S84, S85, and E88 ([@bib2]), NBTI NXL101 resistance mutation GyrA M121K, thiophene resistance mutations GyrB E634, GyrB R630, and P343 ([@bib13]), and the proposed NBTI-gyrase interaction pocket GyrA A68, G72, M75, and M121 ([@bib4]). Interestingly, two of our EN-7^R^ mutations have been reported previously. GyrB D437N results in resistance to QPT-1, etoposide, and AZD0914 ([@bib14]) as well as the spiropyrimidinetrione ETX0914 ([@bib3]), while both GyrB D437N and GyrB K417E mutations result in resistance to NBTI\'s AZ6142, AZ0217, and MCHEM18 ([@bib35]). In addition, a nearby GyrA A32V mutation has been shown to alter sensitivity to these same NBTI molecules ([@bib35]). Structurally, both the GyrB D437N and GyrB K417E mutations are located in the DNA binding TOPRIM domain and directly contact the DNA backbone. The GyrA A34T mutation is found in the winged helix DNA binding domain and interacts with the DNA backbone far from the NBTI binding site, while P219Q is located further from the direct DNA binding site.

To investigate any biological cross-resistance to other gyrase inhibitors we tested the EN-7^R^ strains against ciprofloxacin, novobiocin, and gepotidacin ([Figure 5](#fig5){ref-type="fig"}). We observed no significant cross-resistance with ciprofloxacin or novobiocin. The MICs of ciprofloxacin and novobiocin against the mutants were the same as those against the parent strain, 0.2 and 0.06 μg/mL respectively. However, we observed partial cross-resistance with gepotidacin. The NBTI molecule inhibited growth of the wild-type strain at 0.5 μM. Strains containing GyrA A34T (mut-3 and mut-9), GyrA P219Q (mut-6), and GyrB K417E (mut-1, mut-2, mut-4, and mut-5) exhibited moderate resistance, with MICs of either 4 or 8 μM, while the strains containing GyrB D437N (mut-7 and mut-8) displayed a higher level of resistance with an MIC of 32 μM. This suggests that EN-7 may share resistance elements with gepotidacin.Figure 5Cross-Resistance of EN-7^R^ Strains with Other Gyrase InhibitorsNo observed cross-resistance between EN-7 and other gyrase-targeting antibiotics, ciprofloxacin and novobiocin; however, there is some cross-resistance to the NBTI gepotidacin.

Discussion {#sec4}
==========

In this study, we describe the discovery of a gyrase inhibitor, EN-7, from a screen against *Streptomyces* sporulation septation. We have previously used *Streptomyces* as a small-molecule screening platform for compounds that affect secondary metabolism ([@bib16]) and sporulation ([@bib29]), which is a form of developmentally controlled cell division. *Streptomyces* sporulation employs specific genes that drive changes in cell morphology and fate. However, these sporulation mechanisms also co-opt core macromolecular machinery traditionally employed for vegetative growth and division, exposing unique points of vulnerability. Here, using the classic white (*whi*) phenotype to identify sporulation inhibition, we identify that *S. venezuelae* sporulation is highly sensitive to known antibiotics that directly target DNA or disrupt bacterial gyrase. This is the first report that such diverse forms of DNA damage block sporulation in a streptomycete.

While DNA damage-induced cell division inhibition has been extensively described in other bacteria, such a system is not known within *Streptomyces.* Across diverse bacteria, the SOS response induces the expression of specific proteins that delay cell division. This includes YneA in *B. subtilis* ([@bib31]), SulA in *E. coli* ([@bib6]), SosA in *S. aureus* ([@bib10]), Rv2719c in *Mycobacterium* ([@bib15]), and DivS in *Corynebacterium* ([@bib40]). Although *S. venezuelae* contains homologs to the SOS-response modulators LexA and RecA, no equivalent division inhibitor has yet been identified. However, our findings demonstrate that *S. venezuelae* is very sensitive to a variety of forms of DNA damage and responds by delaying sporulation, likely to prevent passing damaged chromosomes to its progeny.

We then used this effect as a platform for screening small molecules for sporulation inhibition and identified ten active molecules. The most potent of these across both growth inhibition and sporulation inhibition is EN-7, a bacterial topoisomerase inhibitor. EN-7 is highly active against Gram-positive pathogens, including extensively resistant clinical *S. aureus* strains containing resistant elements to fluoroquinolones and numerous other antibiotic classes. Although we did not observe activity against wild-type *E. coli*, an efflux and outer-membrane-deficient strain shows comparable activity with *S. aureus*, suggesting either that the outer-membrane is inhibiting entry of the molecule to the cell or that the compound is being removed from the cell by efflux. We also found no toxicity to human HEK293 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}).

Both genetic and biochemical methods were used to identify DNA gyrase as the target of EN-7. We observe that, in *S. aureus*, EN-7 strongly inhibits gyrase-induced negative supercoiling while having no impact on topoisomerase IV decatenation activity. However, in *E. coli* the molecule inhibits both enzymes while maintaining greater activity against gyrase. This difference in activity across these enzymes in different bacteria can be seen in other topoisomerase inhibitors. For example, ciprofloxacin is more potent against *S. aureus* topoisomerase IV than gyrase ([@bib9]), norfloxacin preferentially targets topoisomerase IV, and nalidixic acid targets gyrase ([@bib23]), whereas in *E. coli*, ciprofloxacin preferentially inhibits gyrase over topoisomerase IV ([@bib32]). Therefore, the strong preference for gyrase inhibition in both Gram-positive and Gram-negative versions of the enzyme distinguishes EN-7 from its traditional counterparts.

Our data show EN-7 to be distinct from classical topoisomerase inhibitors. Our EN-7-resistant *S. aureus* strains do not demonstrate cross-resistance to either ciprofloxacin or novobiocin, and EN-7 is active against ciprofloxacin-resistant clinical *S. aureus* strains that, among other elements, contain the GyrA S84L ciprofloxacin resistance mutation. Unlike ciprofloxacin, EN-7 does not stabilize a double-stranded DNA gyrase cleavage complex and, unlike novobioxin, does not interfere with the ATPase function of gyrase. Despite this significant whole-cell activity, purified *S. aureus* gyrase containing the GyrA S84L mutation shows ∼100-fold resistance to EN-7-induced supercoiling inhibition. Combined with the molecule\'s ability to inhibit gyrase-induced DNA relaxation, this highlights that the biological activity of EN-7 extends beyond inhibiting supercoiling.

There are a growing number of gyrase inhibitors under investigation, including simocylinone D8 ([@bib11]), thiophenes ([@bib13]), imidazopyrazinones ([@bib25]), and the NBTIs ([@bib4]), such as gepotidacin ([@bib8], [@bib22], [@bib44], [@bib26]). These inhibitors act by inhibiting DNA gyrase binding, stabilizing a pre-cleaved complex, or stabilizing DNA cleavage complexes, highlighting the diverse mechanisms of gyrase inhibition. While EN-7 is structurally unique, it shares some superficial structural features with NBTIs, including a quinoline group connected to a heterocycle via a flexible linker region ([Figure S2](#mmc1){ref-type="supplementary-material"}). However, our *in vitro* results show that EN-7 does not act via the same mechanism as these newer gyrase inhibitors. EN-7 does not inhibit DNA gyrase binding, such as simocyclinone D8; does not prevent the formation of fluoroquinolone-induced double-stranded breaks during co-treatment, such as gepotidacin; and does not stabilize a gyrase-DNA cleavage complex, such as imidazopyrazinones and thiophenes. Therefore, EN-7 inhibits topoisomerase activity via a mechanism that is independent from existing molecules.

Beginning with a screen for chemical inhibitors of *S. venezuelae* sporulation we have uncovered a gyrase inhibitor. EN-7 inhibits both gyrase-induced supercoiling and relaxation, stimulates the formation of single-stranded breaks, and inhibits growth of fluoroquinolone-resistant clinical strains. EN-7 may be acting by altering the dynamics of gyrase-induced DNA cleavage and religation by stimulating the formation of single-stranded breaks. However, uncovering the precise mechanisms by which this is inhibiting DNA supercoiling and bacterial growth will require additional structural and biochemical study.

Finally, we suggest that there are many pathways that could be subjected to similar screening methods, including endospore formation in *Bacillus subtilis*, myxospore formation in *Myxococcus xanthus*, and even sporulation programs in eukaryotic organisms such as *Saccharomyces cerevisiae*. Chemical screens against these morphogenetic programs could be a valuable means of identifying new chemical matter of potential clinical interest.

Significance {#sec1}
============

**The rise of antibiotic resistance has led to a significant need for new therapeutics. Here, we describe that *Streptomyces* sporulation is highly sensitive to DNA disrupting antibiotics and how this can be harnessed to identify novel bioactive molecules. The *Streptomyces* genus are filamentous bacteria that exhibit a complex multicellular life cycle, including the growth of vegetative substrate hyphae, erection of a fuzzy layer of aerial hyphae, and a concerted round of cell division that divides each aerial filament into a chain of unigenomic compartments that then mature into spores. We show that antibiotics that directly damage DNA or disrupt DNA gyrase inhibit the developmentally regulated sporulation program. The DNA damage response in *Streptomyces* is not well understood and this finding opens new opportunities to investigate this important biological response. We also leverage this induced morphology to screen a library of small molecules to identify EN-7, a highly active molecule that inhibits bacterial gyrase. Screening against development provides additional targets and assay outputs that are not available to screens based on growth inhibition. It also provides opportunities to identify novel molecules that can inform on the underlying biology of these development programs or provide the basis of much-needed antibiotic development programs.**

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains***Staphylococcus aureus*ATCCATCC 29213*Staphylococcus aureus*[@bib34]RN4220*Staphylococcus aureus*ATCCATCC BAA-1717*Staphylococcus aureus*ATCCATCC 33591*Staphylococcus aureus*Wright Clinical DBC0117*Staphylococcus aureus*Wright Clinical DBC0023*Staphylococcus aureus*Wright Clinical DBC0112*Staphylococcus aureus*Wright Clinical DBC0017*Staphylococcus aureus*Wright Clinical DBC0032*Staphylococcus aureus*Wright Clinical DBC0018*Staphylococcus aureus*Wright Clinical DBC0019*Staphylococcus aureus*Wright Clinical DBC0024*Escherichia coli* MC1061ATCCATCC 53338*Escherichia coli*[@bib18]BW25113*Escherichia coli*[@bib33]ΔtolC ΔbamB*Streptomyces venezuelae*NRRLNRRL B-65442**Chemicals, Peptides, and Recombinant Proteins**CiprofloxacinSigma-AldrichCat\#17850NovobiocinSigma-AldrichCat\#N1628GepotidacinMedChemExpressCat\#HY-16742ChloramphenicolSigma-AldrichCat\#C0378RifampicinSigma-AldrichCat\#R3501TriclosanSigma-AldrichCat\#647950VancomycinSigma-AldrichCat\#V2002KanamycinSigma-AldrichCat\#B5264CCCPSigma-AldrichCat\#C2759Mitomycin CSigma-AldrichCat\#M4287BleomycinSigma-AldrichCat\#B1141000AnhydrotetracyclineSigma-AldrichCat\#A1200000*S.aureus* Gyrase GyrASer84LeuInspiralis Inc.Cat\#SAAS84L01**Critical Commercial Assays**GeneJET Genomic DNA Purification KitThermo ScientificCat\#K0721*E. coli* Gyrase Supercoiling KitInspiralis Inc.Cat\#K0001*S. aureus* Gyrase Supercoiling KitInspiralis Inc.Cat\#SAS4001*S.aureus* Gyrase Cleavage Assay KitInspiralis Inc.Cat\#SAGC001*E. coli* Topo IV Decatenation KitInspiralis Inc.Cat\#D4001*S.aureus* Topo IV Decatenation Assay KitInspiralis Inc.Cat\#SAD4001**Experimental Models: Cell Lines**HEK293CLSCLS 300192**Oligonucleotides***gyrB*\_K417E_F: ATAT[GGTACC]{.ul}ACTCAGGATATGCCACAAATCTThis paperN/AgyrB_K417E_R: ATAT[GCGGCCGC]{.ul}ATCGTGCAATAGACCATTTTGGThis paperN/A**Recombinant DNA**Plasmid: pIMAY[@bib39]Addgene 68939Plasmid: pBR322New England BiolabsCat\#N3033S**Software and Algorithms**GeneiousBiomatters<https://www.geneious.com/>

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Justin Nodwell (<justin.nodwell@utoronto.ca>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

The experimental model that we have employed is *Staphyloccocus aureus* strain ATCC 29213. We have used the cell line HEK293, believed to be female in origin, as a control for EN-7 toxicity against human cells.

Method Details {#sec5.4}
--------------

### Strains, Media and Materials {#sec5.4.1}

*S. venezuelae* was grown on MYM (maltose, yeast extract, malt extract) agar, *B. subtilis* and *E. coli* strains were grown in LB media, *S. aureus* strains were grown in TSB (tryptic soy broth) and BHI (brain heart infusion) agar, and *E. faecalis* strains were grown in both BHI broth and agar.

### Screen for Streptomyces Sporulation Inhibition {#sec5.4.2}

A lawn of *S. venezuelae* spores was plated on MYM agar plates and allowed to dry. For the initial screen, 2 μL of each molecule at 2.5 mM was spotted directly to the agar plate. For known antibiotics or follow-up screening, 10 μL of molecule was added to a drug disk, allowed to dry, and placed on the agar plate. The *S. venezuelae* plate was incubated at 30°C for 48 hours and photographed. The *whi* phenotype was identified by eye. Hits were selected based on their ability to induce a *whi* phenotype at sub-inhibitory concentrations and scored by eye on the size of the induced *whi* region and the zone of inhibition.

### Scanning Electron Microscopy {#sec5.4.3}

To prepare samples for SEM, the agar plate containing a lawn of *S. venezuelae* was cut at the edge of the zone of inhibition and fixed with 2% glutaraldehyde in 0.1% sodium cacodylate buffer followed by sputter coating with gold. Images were obtained and processed using a FEI XL30 ESEM. The contrast of the resulting images was adjusted to highlight the appearance or lack of spore formation.

### Minimum Inhibitory Concentration {#sec5.4.4}

The minimum inhibitory concentration (MIC) defines the lowest concentration of a compound required to inhibit the growth. A single colony of the bacteria being tested was grown in 5 mL of liquid growth media. Following overnight growth, the culture was diluted 100-fold into fresh media and incubated at 37°C until the cells reached mid-log phase (OD~600~ of 0.3 to 0.5). The cells were diluted 10,000-fold into fresh media and the MIC determined for each of the strains by adding 2 μL of the diluted compound to 198 μL of the diluted cells in a clear 96-well plate. The plates were incubated at 37°C overnight and the optical density at 600 nm was measured for each well. All MIC assays were performed in triplicate.

### Isolation of EN-7 Resistant Mutants {#sec5.4.5}

Resistant mutants were generated using both serial passaging and spontaneous mutant methods. For serial passaging, a single colony of *S. aureus* ATCC 29213 was incubated overnight in TSB liquid media at 37°C. Following overnight growth, 2 μL of the overnight culture was diluted into 5 mL of fresh media containing 0.25X MIC of EN-7 and incubated overnight at 37°C. The culture was then diluted into 0.5X MIC EN-7 and the procedure repeated with each subsequent dilution increasing the EN-7 concentration by 2X until reaching 16X MIC of EN-7. This culture was then plated on solid TSB agar and a single colony selected as the mutant strain. For spontaneous mutants, approximately 10^8^ *S. aureus* cells from an overnight culture were plated to BHI agar plate containing 10 μM (10X MIC) EN-7 and incubated overnight at 37°C. The resistance mutation frequency was determined by counting the number of colonies on the EN-7 plates versus the number of colonies of the untreated plates.

### Sequencing of Resistant Mutants {#sec5.4.6}

Genomic DNA was isolated from overnight cultures of the mutant *S. aureus* strains using a GeneJET Genomic DNA Purification Kit from Thermo Scientific. Briefly, 2 mL of overnight culture of *S. aureus* was harvested by centrifuging at 5000 g for 10 minutes. The pellet was resuspended in lysis buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1.2% Triton X-100) with 2 μg/mL lysostaphin and incubated in a water bath at 37°C for 30 minutes. Following incubation, 200 μL of lysis solution with 20 μL Proteinase K was added to each sample and incubated at 56°C for another 30 minutes. Following lysis, 20 μL RNaseA solution was added and allowed to incubate at room temperature for 10 minutes. Addition of 400 μL of 50% ethanol was then followed by DNA isolation and purification on a GeneJET Genomic DNA Purification Column.

Sequencing was performed using an Illumina MiSeq with Nextera XT library preparation and analyzed with Geneious software to map the reads to the *S. aureus* ATCC 29213 assembly (RefSeq GCF_001879295.1) and identify SNPs.

### Confirming Resistance Mutations through Allelic Exchange in *S. aureus* {#sec5.4.7}

The *gyrB* sequence containing the K417E mutation was amplified from EN-7 resistant *S. aureus* mut-1 genomic DNA from the using primers *gyrB*\_K417E_F (ATAT[GGTACC]{.ul}ACTCAGGATATGCCACAAATCT) and gyrB_K417E_R (ATAT[GCGGCCGC]{.ul}ATCGTGCAATAGACCATTTTGG). The amplicon was digested using Fast Digest KpnI and NotI and ligated into the similarly cut pIMAY plasmid. The pIMAY gyrB_K417E plasmid was passaged through *S. aureus* RN4220 at 30°C before being electroporated into ATCC 29213 and also grown at 30°C. A single colony containing the pIMAY plasmid as well as a colony of wild-type *S. aureus* ATCC 29213 were selected and grown separately overnight in 5 mL TSB broth. 100 μL of the overnight cultures were plated to separate 10 mL BHI agar plates containing 1 μg/mL anhydrotetracycline and 10 μM EN-7 and incubated overnight at 37°C. This was to ensure a single-step allelic exchange in the plasmid containing culture. Anhydrotetracycline is used to activate the anti-*secY* sequence in the plasmid and the temperature-sensitive origin of replication prevents replication at 37°C. To confirm that the pIMAY plasmid had been lost, 24 colonies from the transformation plates were replicate plated to a BHI plate containing 10 μM EN-7 and another plate containing both 10 μM EN-7 and 25 μg/mL chloramphenicol, the antibiotic used to select for pIMAY containing cells. The confirm the allelic exchange introduced the single mutation, colony PCR was performed on eight of the 24 colonies using both *gyrB*\_K417E_F and *gyrB*\_K417E_R primers as well as *gyrA*\_A34T_F (ATAT[GGTACC]{.ul}TGCACAGCCACCGTTGTATA) and *gyrA*\_P219Q_R (ATAT[GCGGCCGC]{.ul}TGTGGGCACGATCTTTAGCT) primers. These amplicons were sequenced using an ABI 3730XL instrument.

### *E. coli* Gyrase Supercoiling {#sec5.4.8}

1 U of DNA gyrase was incubated with 0.5 μg of relaxed pBR322 DNA in a 30 μl reaction at 37°C for 30 minutes under the following conditions: 35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl~2~, 2 mM DTT, 1.8 mM Spermidine, 1 mM ATP, 6.5% (w/v) glycerol and 0.1 mg/mL BSA. Each reaction was stopped by the addition of 30 μl chloroform/iso-amyl alcohol (24:1) and 20 μl Stop Dye (40% sucrose, 100 mM Tris.HCl (pH 7.5), 10 mM EDTA, 0.5 μg/mL bromophenol blue), before being loaded on a 1.0% TAE (Tris.acetate 0.04 mM, EDTA 0.002 mM) agarose gel. Gels run at 90 V for 2 hours. Bands were visualized by ethidium staining for 20 minutes and destaining in water for 20 minutes. Gels were scanned using a gel documentation system (GeneGenius, Syngene, Cambridge, UK) and percent inhibition levels obtained with gel scanning software (GeneTools, Syngene, Cambridge,UK).

### *S. aureus* Gyrase Supercoiling {#sec5.4.9}

As for *E. coli* gyrase except assay conditions were: 40 mM HEPES. KOH (pH 7.6), 10 mM magnesium acetate, 10 mM DTT, 2 mM ATP, 500 mM potassium glutamate, and 0.05 mg/mL BSA. Gels run at 80 V for 3 hours.

### *E. coli* Topoisomerase IV Decatenation {#sec5.4.10}

1 U of topoisomerase IV was incubated with 200 ng kDNA DNA in a 30 μl reaction at 37 C for 30 minutes under the following conditions: 50 mM HEPES-KOH (pH 7.6), 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM dithiothreitol, 1 mM ATP and 50 μg/mL BSA. Each reaction was stopped by the addition of 30 μl chloroform/iso-amyl alcohol (24:1) and 20 μl Stop Dye, before being loaded on a 1.0% TAE agarose gel. Gels run at 90 V for 2 hours.

### *S. aureus* Topoisomerase IV Decatenation {#sec5.4.11}

As for E coli topoisomerase IV except assay conditions were: 50 mM Tris-HCl (7.5), 5 mM MgCl~2~, 5 mM DTT, 1.5 mM ATP, 350 mM potassium glutamate and 0.05 mg/mL BSA. Gels run at 80 V for 2 hours.

### *S. aureus* Gyrase Cleavage {#sec5.4.12}

1 U of gyrase was incubated with 0.5 μg of supercoiled pBR322 DNA in a 30 μL reaction at 37 C for 30 minutes under the following conditions: 40 mM HEPES. KOH (pH 7.6), 10 mM magnesium acetate, 10 mM DTT, 100 mM potassium glutamate and 0.05 mg/mL albumin. 0.2 % SDS and 0.1 mg/mL Proteinase K were added before a further incubation at 37°C for 30 minutes. Each reaction was stopped by the addition of 30 μL chloroform/iso-amyl alcohol (24:1) and 20 μL Stop Dye, before being loaded on a 1.0% TAE agarose gel. Gels run at 80 V for 2 hours.

### *S. aureus* Gyrase Relaxation {#sec5.4.13}

1 U of gyrase was incubated with 0.5 μg of supercoiled pBR322 DNA in a 30 μL reaction at 37°C for 60 minutes under the following conditions: 50 mM Tris.HCl (pH 7.5), 5 mM MgCl2,5 mM DTT, 350 mM potassium glutamate, and 0.05 mg/mL albumin. Each reaction was stopped by the addition of 30 μL chloroform/iso-amyl alcohol (24:1) and 20 μl Stop Dye, before being loaded on a 1.0% TAE agarose gel. Gels run at 80 V for 2 hours.

### Synthesis and Characterization of EN-7 {#sec5.4.14}

Compound EN-7 was synthesized by Wuxi PharmaTech, China, from commercially available 5-phenyl isoxazole-3-carboxylic acid (5) and quinolyl 8-carboxaldehyde (1), via the intermediates compounds 2, 3, and 4, using the route shown in [Figure S5](#mmc1){ref-type="supplementary-material"}. A mixture of Compound **1** (4 g, 25.45 mmol, 1 eq) and ethyl 2-(triphenyl-phosphanylidene)acetate (8.87 g, 25.45 mmol, 1 eq) in toluene (40 mL) was stirred at 100°C for 6 h. LCMS showed compound **1** was consumed and the desired mass was detected. The mixture was concentrated to obtain the residue which was purified by column chromatography (SiO2, petroleum ether: ethylacetate =10:1 to 3:1). Compound **2** (4 g, crude) was obtained as a yellow solid. To compound **2** (1.00 g, 4.40 mmol, 1.00 eq) in a solution of EtOH (6 mL) and H2O (2 mL) was added LiOH⋅H2O (923.26 mg, 22.00 mmol, 5.00 eq) and the mixture was stirred at 25°C for 2 h. LCMS showed the reactant 1 was consumed and the desired mass was detected. The solution was poured into water (20 mL), and the aqueous phase was extracted with ethyl acetate (10 mL × 3). The pH of aqueous phase was adjusted to 3 by HCl (4 M), then the precipitate was collected and concentrated *in vacuo*. The mixture was used in the next step without purification. Compound **3** (500 mg, crude) was obtained as a white solid. To a solution of compound **5** (500.00 mg, 2.64 mmol, 1.00 eq) and DMF (1.93 mg, 26.43 μmol, 2.03 μL, 0.01 eq) in THF (10 mL) was added (COCl)~2~ (503.23 mg, 3.96 mmol, 347.05 μL, 1.50 eq), drop-wise, at 0°C, then the mixture was stirred at 25°C for 1 h. NH~2~NH~2~⋅H~2~O (2.5 mL) was added, drop-wise, into the mixture at 0°C, then stirred at 25°C for 1 h. LCMS showed compound **5** was consumed and the desired mass was detected. The residue was poured into water (100 mL) and the aqueous phase was extracted with ethyl acetate (20 mL × 3). The combined organic phase was washed with brine (10 mL), dried with anhydrous Na~2~SO~4~, filtered and concentrated *in vacuo*. The residue was used to the next step without purification. Compound **4** (200 mg, crude) was obtained as a pink solid. To a mixture of compound **3** (80.00 mg, 401.60 μmol, 1.00 eq), Compound **4** (81.60 mg, 401.60 μmol, 1.00 eq), EDCI (76.99 mg, 401.60 μmol, 1.00 eq) in Pyridine (1 mL) was stirred at 50°C for 12 h. LCMS showed Compound **4** was consumed and the desired mass was detected. The mixture was concentrated to obtain the residue, to which was added water (10 mL) and ethyl acetate (5 mL) and the precipitate was collected to obtain the crude product. To the crude product was added MeOH (4 mL) and DMSO (2 drops) and the mixture was stirred at 40°C for 2 h. After filtration, the filter cake was washed with MeOH (5 mL) and concentrated to get the product. Compound EN-7 (40 mg, 97.82 μmol, 24.36% yield, 94% purity) was obtained as a white solid. **MS** (ESI): 385.1 (M+H)+ ^**1**^**H NMR** (400 MHz, DMSO-d6) δ= 10.89 (*br s*, 1H), 10.43 (*br s*, 1H), 9.03 (*br d*, J=2.7 Hz, 1H), 8.78 (*d*, J=16.1 Hz, 1H), 8.46(*br d*, J=8.1 Hz, 1H), 8.18 -- 8.05 (*m*, 2H), 7.98 (*br d*, J=5.7 Hz, 2H), 7.72 (*br t*, J=7.6 Hz, 1H), 7.65 (*dd*, J=4.1, 8.3 Hz, 1H), 7.61- 7.55 (*m*, 3H), 7.49 (*s*, 1H), 7.08 (*d*, J=16.1 Hz, 1H)

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Error was calculated for all measurements in order to confirm that differences that were measured in the presence and absence of antibiotic are statistically meaningful. For example, in [Figures 3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [S3](#mmc1){ref-type="supplementary-material"}, error bars on the absorbance values are derived from at least three replicates. All reported measurements were found to be statistically significant by the criterion of non-overlapping error. We used Prism to make the x-y plots, Pymol for the protein structures, and Adobe Illustrator for the figure layouts.

Data and Code Availability {#sec5.6}
--------------------------

All sequence alterations discovered in the *Staphylococcus* genome mutants are reported in this paper: there are no other significant deviations from the reported genomes. The kits that we have used for *in vitro* gyrase assays (supercoiling and decatenation) are commercially available from Inspiralis Inc. (e.g. catalogue \#s Cat\#SAAS84L01, Cat\#K0001, Cat\#SAS4001, Cat\#SAGC001, Cat\#D4001, Cat\#SAD4001). Any of the raw data used in this work will be made available upon request.

Supplemental Information {#appsec2}
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Document S1. Figures S1--S5 and Table S1Document S2. Article plus Supplemental Information
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